IntelGenx Technologies Corp.
IGX
Rank in Stocks
#28144
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Share Price
$0.17446996
Last synced: 2024-06-11
Market Cap
$26.97M
Change (1 day)
-0.57%
Change (1 year)
2.63%
Country
CA
Trade IntelGenx Technologies Corp. (IGX)
Category
Healthcare
EPS for IntelGenx Technologies Corp. (IGX)
EPS as of March 2024 TTM: $-0.06
According to IntelGenx Technologies Corp. latest financial reports and stock price the company's current EPS (TTM) is $-0.06. At the end of 2022 the company had a EPS of $-0.07 equal to its 2021 EPS that were of $-0.07.
EPS history for IntelGenx Technologies Corp. from 2003 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | 5.33% |
| 2023 | $-0.06 | -21.76% |
| 2022 | $-0.07 | 6.76% |
| 2021 | $-0.07 | -10.53% |
| 2020 | $-0.08 | -41.54% |
| 2019 | $-0.13 | -7.14% |
| 2018 | $-0.14 | 203.69% |
| 2017 | $-0.05 | 149.19% |
| 2016 | $-0.02 | -285.00% |
| 2015 | $0.01 | -136.23% |
| 2014 | $-0.03 | -8.91% |
| 2013 | $-0.03 | -33.11% |
| 2012 | $-0.05 | -19.25% |
| 2011 | $-0.06 | -35.96% |
| 2010 | $-0.09 | 10.75% |
| 2009 | $-0.08 | -43.50% |
| 2008 | $-0.14 | 104.08% |
| 2007 | $-0.07 | 25.87% |
| 2006 | $-0.05 | 5,350.00% |
| 2005 | 0.00 | -80.77% |
| 2004 | $-0.01 | 5,100.00% |
| 2003 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -27,505.06% |
US
|
|
| $-7.98 | 12,526.58% |
US
|
|
| $-5.29 | 8,270.25% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -43,992.41% |
NL
|
